1991
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaLomustineMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission InductionStreptozocinSurvival RateVincristineConceptsAdvanced-stage Hodgkin's diseaseErythrocyte sedimentation rateDose intensityOverall survivalHodgkin's diseaseInitial erythrocyte sedimentation rateDisease-free survival ratesDisease-free survival curvesComplete response rateDisease-free survivalBetter overall survivalPoor prognostic factorSecondary acute leukemiaHigher platelet countsAssessable patientsPrognostic factorsPlatelet countAcute leukemiaTreatment outcomesMOPPPatientsResponse rateSurvival rateSurvival curvesDisease
1977
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy
Fisher R, DeVita V, Johnson B, Simon R, Young R. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. The American Journal Of Medicine 1977, 63: 177-182. PMID: 70170, DOI: 10.1016/0002-9343(77)90230-3.Peer-Reviewed Original Research